Learn about our healthcare areas

Explore medicine and therapy products
Explore MedTech products

Find our latest news, stories and press releases

Delivering long-term value for our stakeholders

Explore career opportunities and more

Impacting health for humanity

Search Results

No Results

    Recently Viewed

      Listening...

      Sorry, I don't understand. Please try again
      1. Home/
      2. Media Center/
      3. Press releases /
      4. Innovative Medicine

      Innovative Medicine

      Innovative Medicine
      June 12, 2014

      Janssen Collaborates With ViiV Healthcare To Develop Two-Drug Single Tablet Regimen For The Maintenance Treatment Of People Living With HIV

      Learn more
      Innovative Medicine
      June 2, 2014

      Ibrutinib (IMBRUVICA®) Three Year Follow-up of Single-Agent and Combination Study Results in Chronic Lymphocytic Leukemia

      Oral presentation (Abstract 7014) and poster session (Abstract 7009) featured at the 50th annual meeting of the American Society of Clinical Oncology
      Learn more
      Innovative Medicine
      June 2, 2014

      Ibrutinib (IMBRUVICA®) RESONATET™ Data Show Significant Improvements in Progression-Free Survival and Overall Survival in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

      Phase 3 data (Abstract LBA7008) featured in the official press program of the 50th annual meeting of the American Society of Clinical Oncology and simultaneously published in The New England Journal of Medicine
      Learn more
      Innovative Medicine
      June 2, 2014

      IMAAGEN Data Demonstrate that Abiraterone Acetate Plus Prednisone (5mg once daily) Lowers PSA Levels in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer (M0-CRPC)

      Phase 2 study data presented at the 50th annual meeting of the American Society of Clinical Oncology
      Learn more
      Innovative Medicine
      May 21, 2014

      Janssen Withdraws Application In European Union Seeking Approval Of Intravenously Administered Simponi®

      Learn more
      Innovative Medicine
      May 16, 2014

      OLYSIO™ (simeprevir) receives marketing authorisation in the European Union for the treatment of adults with hepatitis C genotype 1 and 4 infection

      Simeprevir provides a new triple therapy treatment option, as well as the first ever 12-week interferon-free and ribavirin independent treatment regimen, in combination with sofosbuvir, for appropriate patients in Europe
      Learn more
      Research
      May 14, 2014

      Janssen Labs Expanding and Accelerating Coast to Coast -- Unveils Plan to Enhance the Innovation Ecosystem with New Incubator in South San Francisco and Awards One Year of Lab Space to Three Innovative Healthcare Companies in Boston

      Learn more
      Innovative Medicine
      May 13, 2014

      Supplemental New Drug Applications for Once-Monthly Long-Acting Therapy INVEGA® SUSTENNA® (paliperidone palmitate) Submitted to the U.S. FDA for the Treatment of Schizoaffective Disorder

      New submission based on positive data from a 15-month schizoaffective relapse prevention study
      Learn more
      Innovative Medicine
      May 7, 2014

      Janssen Submits Supplemental New Drug Application to U.S. FDA for OLYSIO™ (Simeprevir) for Once-Daily Use in Combination with Sofosbuvir for 12 Weeks for the Treatment of Adult Patients with Genotype 1 Chronic Hepatitis C

      Filing Includes Data from Treatment-Naïve Patients with Advanced Fibrosis and Null Responders with All Stages of Liver Fibrosis
      Learn more
      Load more